Literature DB >> 3011910

Germ-line sequence of the DH segment employed in Ars-A antibodies: implications for the generation of junctional diversity.

N F Landolfi, J D Capra, P W Tucker.   

Abstract

The majority of antibodies produced by A/J mice in response to p-azophenylarsonate belong to the Ars-A family. These antibodies have the conserved sequence cys-ala-arg-ser-x-tyr-tyr (in which x is variable) spanning the V-D junction of the heavy chain. The cys-ala-arg residues are accounted for in the sequence of the A/J VH gene; the tyr-tyr are believed to be specified by the A/J DH segment, although this assumption is based on the DFL16.1 sequence derived from BALB/c mice. This implies that the ser-x is generated by joining imprecision and/or N segment addition. More recent data have revealed that the codon specifying the junctional serine residue is highly conserved (TCN, where N is usually G), suggesting a germline origin. Because there is no obvious way to generate this codon from the A/J Ars-A VH gene, we examined the involvement of the A/J DH segment in the generation of this junctional residue by cloning and sequencing the A/J equivalent to DFL16.1. We have established that this DH segment is polymorphic among BALB/c and A/J at the nucleic acid sequence level, and that it does not encode the junctional serine. This implies that a mechanism other than joining imprecision or random N segment addition operates at V-D junctions of Ars-A heavy chains.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011910

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  V kappa and J kappa gene segments of A/J Ars-A antibodies: somatic recombination generates the essential arginine at the junction of the variable and joining regions.

Authors:  I Sanz; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

2.  Identity of the V kappa 10-Ars-A gene segments of the A/J and BALB/c strains.

Authors:  K Meek; I Sanz; G Rathbun; A Nisonoff; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

3.  Three-dimensional structure of Fab R19.9, a monoclonal murine antibody specific for the p-azobenzenearsonate group.

Authors:  M B Lascombe; P M Alzari; G Boulot; P Saludjian; P Tougard; C Berek; S Haba; E M Rosen; A Nisonoff; R J Poljak
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

Review 4.  Restricted, canonical, stereotyped and convergent immunoglobulin responses.

Authors:  Carole J Henry Dunand; Patrick C Wilson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-05       Impact factor: 6.237

5.  Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsonate antibody 200-fold.

Authors:  J Sharon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  Lack of connectivity between the induced and autoimmune repertoires of lpr/lpr mice.

Authors:  D L Very; D J Panka; D Weissman; L Wysocki; T Manser; A Marshak-Rothstein
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

7.  Organization of the murine immunoglobulin VH complex in the inbred strains.

Authors:  G A Rathbun; J D Capra; P W Tucker
Journal:  EMBO J       Date:  1987-10       Impact factor: 11.598

8.  Single germline VH and V kappa genes encode predominating antibody variable regions elicited in strain A mice by immunization with p-azophenylarsonate.

Authors:  L J Wysocki; T Gridley; S Huang; A G Grandea; M L Gefter
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307

9.  Influence of the macromolecular form of a B cell epitope on the expression of antibody variable and constant region structure.

Authors:  S Fish; T Manser
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

10.  Tracing the development of single memory-lineage B cells in a highly defined immune response.

Authors:  A H Liu; P K Jena; L J Wysocki
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.